much writing zyprexa documents appeared new york times times london chiming well couple choice cuts one document dated october robert baker senior lilly clinical research physician mailed colleagues meeting academic advisory board attended atlanta reinforced impression hyperglycemia remains quite threat olanzapine may merit increasing even medical attention marketing focus topic dr baker added board quite impressed magnitude weight gain olanzapine implications glucose another internal document dated october described risk weight gain top threat zyprexa link background